Orient Europharma Co., Ltd. 4120

TPEX · Taiwan · Health Technology

TWD 46.10+0.10 (+0.22%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Orient Europharma Co., Ltd. 4120

TPEX · Taiwan · Health Technology

TWD 46.10+0.10 (+0.22%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-1.71% · 6MFull-screen chart

Open TWD 46.00High TWD 46.20Low TWD 46.00Close TWD 46.10Volume 58.72K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: TWD 46.00
Day range: TWD 46.00 – TWD 46.20
52-week range: TWD 42.60 – TWD 50.60
Volume: 58.72K
Market cap: TWD 3.99B
Dividend yield (annualized): 8.71%
Avg. volume (1Y): 37.08K

Performance

1 week

0.00%

1 month

-2.54%

3 months

+9.09%

6 months

+6.10%

Year to date

+12.76%

1 year

-0.61%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Taiwan
Exchange: TPEX
Shares outstanding: 86.75M
ISIN: TW0004120001
Beta: 0.06

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJul 07, 2026

TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan

TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) has officially received a Drug License Collection Notice from the Taiwan Food and Drug Administration (TFDA). Its commercialization partner, Orient EuroPharma Co., Ltd. ("Orient EuroPharma"; TPEX: 4120), will complete the required procedures to obtain the drug license in accordance with TFDA regulations, marking

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.